1
|
Png CW, Weerasooriya M, Guo J, James SJ, Poh HM, Osato M, Flavell RA, Dong C, Yang H, Zhang Y. DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis. Oncogene 2015; 35:206-17. [PMID: 25772234 DOI: 10.1038/onc.2015.74] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2014] [Revised: 01/04/2015] [Accepted: 02/05/2015] [Indexed: 02/07/2023]
Abstract
Dual specificity phosphatase 10 (DUSP10), also known as MAP kinase phosphatase 5 (MKP5), negatively regulates the activation of MAP kinases. Genetic polymorphisms and aberrant expression of this gene are associated with colorectal cancer (CRC) in humans. However, the role of DUSP10 in intestinal epithelial tumorigenesis is not clear. Here, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Krüppel-like factor 5 (KLF5) expression in IEC. In line with increased IEC proliferation, DUSP10 KO mice developed more colon tumours with increased severity compared with WT mice in response to administration of DSS and azoxymethane (AOM). Furthermore, survival analysis of CRC patients demonstrated that high DUSP10 expression in tumours was associated with significant improvement in survival probability. Overexpression of DUSP10 in Caco-2 and RCM-1 cells inhibited cell proliferation. Our study showed that DUSP10 negatively regulates IEC growth and acts as a suppressor for CRC. Therefore, it could be targeted for the development of therapies for colitis and CRC.
Collapse
Affiliation(s)
- C W Png
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore
| | - M Weerasooriya
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore
| | - J Guo
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - S J James
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore
| | - H M Poh
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore
| | - M Osato
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - R A Flavell
- Department of Immunology, Howard Hughes Medical Institute, Yale University, New Haven, CT, USA
| | - C Dong
- Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing, China
| | - H Yang
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - Y Zhang
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore
| |
Collapse
|